JP2009515992A - キナーゼ阻害剤として有用なアミノピリミジン - Google Patents

キナーゼ阻害剤として有用なアミノピリミジン Download PDF

Info

Publication number
JP2009515992A
JP2009515992A JP2008541363A JP2008541363A JP2009515992A JP 2009515992 A JP2009515992 A JP 2009515992A JP 2008541363 A JP2008541363 A JP 2008541363A JP 2008541363 A JP2008541363 A JP 2008541363A JP 2009515992 A JP2009515992 A JP 2009515992A
Authority
JP
Japan
Prior art keywords
ring
aliphatic
compound
optionally substituted
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008541363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009515992A5 (enExample
Inventor
ダミアン フレイズ，
アンドリュー ミラー，
ダニエル ロビンソン，
ジョアン ピンダー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2009515992A publication Critical patent/JP2009515992A/ja
Publication of JP2009515992A5 publication Critical patent/JP2009515992A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2008541363A 2005-11-16 2006-11-16 キナーゼ阻害剤として有用なアミノピリミジン Pending JP2009515992A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73706405P 2005-11-16 2005-11-16
PCT/US2006/044636 WO2007059299A1 (en) 2005-11-16 2006-11-16 Aminopyrimidines useful as kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2009515992A true JP2009515992A (ja) 2009-04-16
JP2009515992A5 JP2009515992A5 (enExample) 2011-01-06

Family

ID=37806123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008541363A Pending JP2009515992A (ja) 2005-11-16 2006-11-16 キナーゼ阻害剤として有用なアミノピリミジン

Country Status (9)

Country Link
US (1) US20070179125A1 (enExample)
EP (1) EP1951716B1 (enExample)
JP (1) JP2009515992A (enExample)
CN (1) CN101360740A (enExample)
AT (1) ATE508126T1 (enExample)
AU (1) AU2006315334B2 (enExample)
CA (1) CA2629781A1 (enExample)
DE (1) DE602006021776D1 (enExample)
WO (1) WO2007059299A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010513567A (ja) * 2006-12-19 2010-04-30 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なアミノピリミジン

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2266258T3 (es) 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2004072029A2 (en) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
EP1951234A2 (en) * 2005-10-18 2008-08-06 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase
WO2007056163A2 (en) 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CN102861338A (zh) * 2006-04-05 2013-01-09 诺瓦提斯公司 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
EP2016070B1 (en) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
MX2009004807A (es) 2006-11-02 2009-06-15 Vertex Pharma Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
ATE526328T1 (de) 2007-03-09 2011-10-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
WO2008112642A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
WO2008112646A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
CA2683785A1 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
MX2009011812A (es) 2007-05-02 2010-01-14 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
CA2685876A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
AU2008262291A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
AR067762A1 (es) 2007-07-31 2009-10-21 Vertex Pharma Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
US20110190280A1 (en) * 2007-08-29 2011-08-04 George Adjabeng Thiazole And Oxazole Kinase Inhibitors
UA101166C2 (ru) 2007-09-21 2013-03-11 Аррей Биофарма Инк. Производные пиридин-2-иламино-1,2,4-тиадиазола как активаторы глюкокиназы для лечения сахарного диабета
WO2009073224A1 (en) * 2007-12-07 2009-06-11 Ambit Biosciences Corp. Methods of treating certain diseases using pyrimidine derivatives
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010009985A2 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137844A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135984A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
EP2411011A4 (en) * 2009-03-24 2012-08-15 Msd Kk NEW AMINO-PYRIDINE DERIVATIVES WITH SELECTIVE AURORA A INHIBITION
MX2014002208A (es) 2011-08-25 2014-05-28 Hoffmann La Roche Inhibidores de serina/treonina quinasa.
RU2014129740A (ru) 2011-12-22 2016-02-10 Ф.Хоффманн-Ля Рош Аг Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы
TW201341367A (zh) 2012-03-16 2013-10-16 Axikin Pharmaceuticals Inc ３，５－二胺基吡唑激酶抑制劑
SI3459942T1 (sl) 2012-04-24 2021-05-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
WO2013186726A2 (en) * 2012-06-15 2013-12-19 Basf Se Multicomponent crystals comprising dasatinib and selected cocrystal formers
HUE041544T2 (hu) 2013-03-12 2019-05-28 Vertex Pharma DNS-PK inhibitorok
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
PT3424920T (pt) 2013-10-17 2020-07-07 Vertex Pharma Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kináz inhibitorok
CA2988306A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
KR101726648B1 (ko) * 2016-02-29 2017-04-14 한국화학연구원 신규한 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 drak 관련 질환의 예방 또는 치료용 약학적 조성물
TWI726094B (zh) 2016-04-28 2021-05-01 美商施萬生物製藥研發Ｉｐ有限責任公司 作為jak激酶抑制劑之嘧啶化合物
JP2019529475A (ja) 2016-09-27 2019-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法
EP3562821B9 (en) 2016-12-28 2021-05-26 Minoryx Therapeutics S.L. Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
CN106841420A (zh) * 2016-12-30 2017-06-13 广州中大南沙科技创新产业园有限公司 一种LC‑MS/MS测定大鼠血浆中Ly‑7u浓度的方法
WO2019084383A1 (en) 2017-10-27 2019-05-02 Theravance Biopharma R&D Ip, Llc PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS
JP2022502496A (ja) * 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤組成物、作製方法、および使用方法
HUE066802T2 (hu) 2019-04-24 2024-09-28 Theravance Biopharma R&D Ip Llc JAK kináz inhibitor észter és karbonát pirimidin vegyületek
WO2020219640A1 (en) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Pyrimidine jak inhibitors for the treatment of skin diseases
US20230322722A1 (en) * 2020-08-26 2023-10-12 Nalo Therapeutics Modulators of myc family proto-oncogene protein
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023164612A1 (en) * 2022-02-25 2023-08-31 Nalo Therapeutics Modulators of myc family proto-oncogene protein

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519143A (ja) * 1999-12-28 2003-06-17 ファーマコピーア，インコーポレーティッド ピリミジン及びトリアジン系キナーゼ阻害剤
US6653301B2 (en) * 2000-12-21 2003-11-25 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2004000833A1 (en) * 2002-06-20 2003-12-31 Vertex Pharmaceuticals Incorporated Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase
JP2005500294A (ja) * 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
WO2005040159A1 (en) * 2003-10-17 2005-05-06 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056163A2 (en) * 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519143A (ja) * 1999-12-28 2003-06-17 ファーマコピーア，インコーポレーティッド ピリミジン及びトリアジン系キナーゼ阻害剤
US6653301B2 (en) * 2000-12-21 2003-11-25 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2004518743A (ja) * 2000-12-21 2004-06-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
JP2005500294A (ja) * 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
WO2004000833A1 (en) * 2002-06-20 2003-12-31 Vertex Pharmaceuticals Incorporated Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase
WO2005040159A1 (en) * 2003-10-17 2005-05-06 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010513567A (ja) * 2006-12-19 2010-04-30 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なアミノピリミジン

Also Published As

Publication number Publication date
WO2007059299A1 (en) 2007-05-24
US20070179125A1 (en) 2007-08-02
CA2629781A1 (en) 2007-05-24
EP1951716B1 (en) 2011-05-04
AU2006315334B2 (en) 2011-05-19
DE602006021776D1 (de) 2011-06-16
EP1951716A1 (en) 2008-08-06
AU2006315334A1 (en) 2007-05-24
ATE508126T1 (de) 2011-05-15
CN101360740A (zh) 2009-02-04

Similar Documents

Publication Publication Date Title
AU2006315334B2 (en) Aminopyrimidines useful as kinase inhibitors
JP5328361B2 (ja) キナーゼインヒビターとして有用なアミノピリミジン
JP5389785B2 (ja) キナーゼ阻害剤として有用なチアゾールおよびピラゾール
JP5572087B2 (ja) キナーゼ阻害として有用なアミノピリミジン
EP2152696B1 (en) Aminopyrimidines useful as kinase inhibitors
US8455507B2 (en) Aminopyrimidines useful as kinase inhibitors
JP2013237703A (ja) キナーゼ阻害薬として有用なアミノピリミジン
CA2687966A1 (en) Thiazoles and pyrazoles useful as kinase inhibitors
JP2013526540A (ja) Ａｔｒキナーゼ阻害剤として有用な化合物
HK1125107A (en) Aminopyrimidines useful as kinase inhibitors
US20140037754A1 (en) Aminopyrimidines useful as kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120608

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120907

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120914

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121207